Clinical trials for Bladder / Urinary Tract / Urethral cancer
130 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT05489211
#2022-000776-19
Cancer urothélial (sous-étude 6)
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
2 recruiting sites
AstraZeneca
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT03767075
#2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
EGFR
FGFR
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT06833073
#2024-517335-46-00
Required histologic types
Non-invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Surgery
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT03547973
#2023-508302-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
19 recruiting sites
Gilead Sciences
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06653777
#2024-512729-10-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04428554
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Institut Claudius Regaud
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT06511648
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Radiotherapy
4 recruiting sites
Groupe espagnol d'oncologie génito-urinaire
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04617756
Required histologic types
Upper excretory tract cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
9 recruiting sites
Centre Hospitalier Universitaire de Nîmes
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04752722
#2024-512900-20-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Systemic Treatment-Naive
Immunotherapy
4 recruiting sites
enGene, Inc.
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04752722
#2024-512900-20-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
2
3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
4 recruiting sites
enGene, Inc.